Merrimack Pharmaceuticals, Inc. announced today that the last patient has been enrolled in the second cohort of a two-cohort randomized Phase 2 clinical trial of MM-121 in combination with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer.
Increasing financial and administrative pressures-exacerbated by the federal sequester and continued rollout of the Affordable Care Act-have created instability and uncertainty for oncology practices nationwide.
A study of three diverse primary care practices tests the effectiveness of having doctors recommend counseling for colorectal cancer screening. Results found many patients do not follow through with the referral, but for those that do, some change their mind and have a test they might have avoided.
Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015, this includes a plan for new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions.
At a time of controversy regarding the value of PSA screening in the early detection of prostate cancer, the AUA has issued a new clinical guideline on the subject and launched an educational campaign designed to share the information with urologists and their patients.
Marijuana users had a small but statistically lower risk of bladder cancer compared with people who smoked tobacco or did not smoke.
Merrimack Pharmaceuticals is combining biology, computing, and engineering in order to gain a comprehensive understanding of the dynamics of different types of cancer and then use that information to develop new therapeutics.
Updates on new dosing strategies, formulations, and other information on treatments for patients with non-Hodgkin lymphoma, indolent B-cell non-Hodgkin lymphoma, and myelofibrosis.
The standard of care for metastatic renal cell carcinoma (RCC) prevailed in a randomized comparison of everolimus (Afinitor) and sunitinib (Sutent) as first-line therapy
Recently, Girish M. Shah's team has been using cellular and murine models to examine various therapeutic options, including inhibitor and gene knockout approaches against the DNA damage-responsive enzyme poly(ADP-ribose) polymerase 1 (PARP-1).
Puma Biotechnology is a Los Angeles-based development stage biopharmaceutical company that has spent the last couple of years focused on the development of its lead drug candidate, neratinib (PB272).
Sunnyvale, California-based Pharmacyclics has yet to lay claim to any FDA-approved therapeutics since it was formally incorporated in 1991, but that may very well change in the near future as a first-in-class drug for certain B-cell malignancies is proving quite effective in clinical trials.
The value of nursing in symptom management is so important and becoming increasingly so, as the treatment becomes more complex.
An approximately 20% increase was seen in both community oncology clinics closing and merging with hospitals, demonstrating a continuing trend toward the consolidation of cancer care delivery.
While competition is the hallmark of the powerhouse sports teams of the Big Ten Conference, collaboration will be the key for a research initiative recently launched by cancer centers at most of the same universities.
At the 2013 ASCO Annual Meeting, researchers presented the latest developments with enzalutamide, radium-223, and abiraterone acetate as treatments for patients with advanced prostate cancer.
Adding ibrutinib to standard R-CHOP chemotherapy for non-Hodgkin lymphoma resulted in an objective response rate of 100% in the first-line setting.
A dual-target PI3 kinase inhibitor known as IPI-145 demonstrated activity in several types of relapsed and refractory non-Hodgkin lymphoma.
The biopharmaceutical industry has 241 medicines in development for the treatment of leukemia, lymphoma, myeloma, and other blood cancers, which together are expected to comprise 9%, or 150,000, of new oncologic diagnoses in America this year.
Exploratory analyses by intrinsic subtype showed that HER2-positive breast cancer is molecularly heterogeneous with varying degrees of sensitivity to HER2-targeted therapy.
Gifts to healthcare providers, including lunches, are now required to be tracked and reported.
An assay based on a prostate-specific antigen isoform performed significantly better than did conventional PSA measures for detecting prostate cancer and identifying histopathologically aggressive cancers.
The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.
An assay based on tumor genetics showed potential for stratifying risk in prostate cancer patients and aiding selection of men for active surveillance.
Adding the mTOR inhibitor everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer, and in the process, provided clues to the origin of trastuzumab resistance.
With more and more cancer therapies being administered as oral agents, oncology nurses have a critical role to play in helping their patients to manage their medications and any side effects of treatment.
An analysis of more than 13,000 patients with ovarian cancer found that only around 37% of patients receive care that adheres to the NCCN guidelines.
Albert S. Baldwin, Jr, PhD, focuses on understanding the regulation and biological functions of NF-κB and its role in disease, particularly in cancer, in a laboratory he heads at the UNC Lineberger Comprehensive Cancer Center.
Women with advanced ovarian cancer lived almost a year longer when treated with intraperitoneal chemotherapy instead of intravenous therapy.
Highlights of key findings from several phase I clinical trials that provide insight into new and emerging druggable targets and targeted therapies.